Frankfurt At least with the vaccines against Covid-19, things are progressing: This week, the two partners Biontech and Pfizer, as well as competitor Moderna, reported efficiencies of around 95 percent and want to submit approval applications soon.
While a breakthrough is emerging in the development of vaccines, the search for drugs to combat the virus is proving difficult. The results of research and clinical tests to date are disappointing.
The search for drugs is no less extensive than in the vaccine area. Of the 3,900 Covid studies listed in the Clinical.Trials database, more than 90 percent deal with therapeutic measures against Covid – and less than ten percent with vaccines.
Measured against this, the progress in the treatment of Covid patients has so far been poor. At least this is what the clinical results to date and the still comparatively high mortality rate, the lethality, in Covid-19 diseases indicate.
Months ago, former heads of the US Food and Drug Administration (FDA) criticized the fact that the search for drugs globally is too bogus and that it may be wasting resources. The successful vaccine projects could now mean that drug developers are running out of time. The faster you vaccinate, the less you can earn on medication.
Corona deaths: what the statistics say
In contrast to the figures in the graph, if you look at the monthly averages offset by three weeks – for example, the number of deaths in the 30 days up to November 17th in relation to the monthly new infections up to October 27th – is the death rate fell from more than five percent in April and May to less than 0.5 percent in the summer months, but has since increased to just under two percent.
And this despite the fact that the number of tests has risen steadily over the course of the year, which tends to lower the death rate due to the resulting increase in the number of positive but harmless infections that have been tested.
Read on now
Get access to this and every other article in
Web and in our app for 4 weeks free of charge.